NCT02352493 - A Phase 1/2 Study of an Investigational Drug, ALN-CC5, in Healthy Adult Volunteers and Patients With PNH | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

April 30, 2016

Study Completion Date

August 31, 2017

Conditions

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Interventions

DRUG

ALN-CC5

Single or multiple doses of ALN-CC5 by subcutaneous (sc) injection

DRUG

Sterile Normal Saline (0.9% NaCl)

calculated volume to match active comparator

Trial Locations (4)

Clinical Trial Site, Barcelona

Clinical Trial Site, Leeds

Covance Clinical Research Unit, Leeds

Richmond Pharmacology, London